RELAY THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENTIndemnification Agreement • June 24th, 2020 • Relay Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ] by and between Relay Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 24th, 2020 • Relay Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Relay Therapeutics, Inc., a Delaware corporation (the “Company”), and Sanjiv K. Patel, M.A., M.D., MBA (the “Executive”) and is effective as of the date it becomes fully executed by the parties hereto (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment letter agreement between the Executive and the Company dated February 11, 2017 (the “Prior Agreement”), and (ii) any offer letter, employment agreement or severance agreement.
RELAY THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 24th, 2020 • Relay Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 19, 2018, by and among Relay Therapeutics, Inc., a Delaware corporation (the “Company”), each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Preferred Investor”, and the stockholders that are now or in the future listed on Schedule B hereto, if any, which are referred to in this Agreement as the “Common Investor”, and together with the Preferred Investors, each an “Investor” and collectively, the “Investors”.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Collaboration and License Agreement • June 24th, 2020 • Relay Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Collaboration and License Agreement (the “Agreement”) is effective as of June 15, 2020 (the “Restatement Date”), by and between D. E. Shaw Research, LLC, a Delaware limited liability company located at 120 West 45th Street, 39th Floor, New York, NY 10036 (“DESRES”), and Relay Therapeutics, Inc., a Delaware corporation located at 399 Binney Street, Cambridge, MA 02139 (“Company”). DESRES and Company are each sometimes referred to herein as a “Party” or collectively as the “Parties”.
